Clinical Trial for Brain Cancer Glioblastoma Immunotherapy SurVaxM

Roswell Park Spinoff Company Advances Toward New Clinical Trial for Brain Cancer Immunotherapy SurVaxM MimiVax LLC and Roswell Park to launch large clinical trial at centers in U.S. & abroad following major licensing deal MimiVax LLC secures $10 million upfront in licensing deal Large phase II studies expected

Read more

Promising Vaccine Therapy for Glioblastoma Brain Cancers Moves on to Larger, Multisite Study

Phase II clinical trial will assess efficacy of Roswell Park-developed immunotherapy in newly diagnosed patients BUFFALO, N.Y. — An innovative vaccine therapy developed at Roswell Park Cancer Institute (RPCI) is being tested in a multisite clinical trial involving 50 patients with newly diagnosed glioblastoma brain tumors. The

Read more